Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +72

Amgen stock last trades at USD 418.60 on September 28, 2026

Clinical trial results Drug approval AI-generated analysis

📈 Amgen stock traded at USD 418.60 on September 28, 2026, gaining 0.96% from the prior close of USD 414.61.

✅ The FDA approved an update to IMDELLTRA prescribing information on September 14, 2026, reducing monitoring requirements from 22-24 hours to 6-8 hours for the first two doses.

🔬 Amgen's Phase 3 DeLLphi-305 study met its primary endpoint at an interim analysis in early September 2026, showing statistically significant overall survival improvement with IMDELLTRA plus Imfinzi.

📊 The DeLLphi-305 trial randomized 563 patients and successfully met secondary endpoints for progression-free survival and objective response rate.

💼 Amgen's combination therapy of IMDELLTRA with AstraZeneca's Imfinzi demonstrated enhanced efficacy compared to Imfinzi alone in the pivotal study.

Bullish Signals
  • Amgen received FDA approval on September 14, 2026, to reduce monitoring time for IMDELLTRA from 22-24 hours to 6-8 hours, streamlining clinical administration and potentially improving patient compliance.
  • The Phase 3 DeLLphi-305 study met its primary endpoint of statistically significant overall survival improvement when IMDELLTRA was combined with AstraZeneca's Imfinzi compared to Imfinzi alone.
  • Amgen successfully achieved secondary endpoints in the DeLLphi-305 trial, including progression-free survival and objective response rate, validating the combination therapy's efficacy across 563 randomized patients.
Full Analysis
Amgen Inc. stock closed at USD 418.60 on September 28, 2026, representing a gain of 0.96% from the previous close of USD 414.61. The trading activity reflects ongoing investor interest in the biotechnology firm's pipeline developments and regulatory milestones. Significant progress was made for Amgen's IMDELLTRA therapy following an FDA approval on September 14, 2026, which updated prescribing information to reduce recommended monitoring time from 22 to 24 hours to just 6 to 8 hours in a healthcare setting. This regulatory change streamlines administration protocols and could enhance the drug's operational efficiency. Earlier in September, Amgen announced positive interim results for its Phase 3 DeLLphi-305 study involving IMDELLTRA combined with AstraZeneca's Imfinzi. The trial met its primary endpoint of statistically significant improvement in overall survival compared to Imfinzi alone, while also achieving secondary endpoints for progression-free survival and objective response rate across 563 randomized patients. These developments highlight Amgen's strategic advancements in oncology treatments, potentially strengthening its market position by improving patient outcomes and reducing clinical monitoring burdens. The combination therapy results suggest a robust efficacy profile that could influence future prescribing patterns and competitive dynamics within the immunotherapy sector.